Rabeprazole extended-release 50 mg compared with esomeprazole 40 mg and rabeprazole delayed release 20 mg

被引：1

作者：

Yuan, Y. ^{[1
]}

Hunt, R. H. ^{[1
]}

机构：

[1] McMaster Univ, Hlth Sci Ctr, Div Gastroenterol, Farncombe Family Digest Dis Res Inst, Hamilton, ON, Canada

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2011年 / 33卷 / 10期

关键词：

CELIAC-DISEASE; TUBERCULOSIS; COHORT; RISK;

D O I：

10.1111/j.1365-2036.2011.04622.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1177 / +

页数：2

共 50 条

[21] Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn
Warrington, S.
Baisley, K.
Lee, D.
Lomax, K.
Delemos, B.
Boyce, M.
Morocutti, A.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (04) : 511 - 517
[22] Comparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg
Kukulka, Michael
Eisenberg, Corey
Nudurupati, Sai
[J]. CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2011, 4 : 213 - 220
[23] Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH in H. pylori positive PPI extensive metabolizers
Isakov, VA
Morozov, SV
Tsodikova, OM
Guschin, AE
[J]. GASTROENTEROLOGY, 2004, 126 (04) : A340 - A340
[24] Niacin Extended-Release/Simvastatin (2000/40 mg) Combination Therapy Produces Larger Favorable Changes in Lipoprotein Particles Compared to Atorvastatin Monotherapy (40 mg)
Toth, Peter
Doan, Thao T.
Jiang, Ping
[J]. DIABETES, 2011, 60 : A191 - A192
[25] Acid-suppressive efficacy of a reduced dosage of rabeprazole: Comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry
Shimatani, T
Inoue, M
Kuroiwa, T
Xu, J
Tazuma, S
Horikawa, Y
Nakamura, M
[J]. DIGESTIVE DISEASES AND SCIENCES, 2005, 50 (07) : 1202 - 1206
[26] Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study
Lim, Hyun
Park, Jong Kyu
Chung, Hyunsoo
Lee, Si Hyung
Park, Jae Myung
Park, Jung Ho
Kim, Gwang Ha
Shin, Sung Kwan
Hong, Su Jin
Lee, Kwang Jae
Park, Moo In
Jung, Hye-Kyung
Kim, Hyun-Soo
Sung, Jae Kyu
Jeon, Seong Woo
Choi, Suck Chei
Moon, Jeong Seop
Kim, Nayoung
Park, Jong-Jae
Hong, Sung Hee
Kim, Na Young
Jung, Hwoon-Yong
[J]. BMC GASTROENTEROLOGY, 2023, 23 (01)
[27] Acid-Suppressive Efficacy of a Reduced Dosage of Rabeprazole: Comparison of 10 Mg Twice Daily Rabeprazole with 20 Mg Twice Daily Rabeprazole, 30 Mg Twice Daily Lansoprazole, and 20 Mg Twice Daily Omeprazole by 24-Hr Intragastric pH-metry
Tomohiko Shimatani
Masaki Inoue
Tomoko Kuroiwa
Jing Xu
Susumu Tazuma
Yoko Horikawa
Masuo Nakamura
[J]. Digestive Diseases and Sciences, 2005, 50 : 1202 - 1206
[28] Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia
Isaacsohn, JL
LaSalle, J
Chao, G
Gonasun, L
[J]. CLINICAL THERAPEUTICS, 2003, 25 (03) : 904 - 918
[29] Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study
Hyun Lim
Jong Kyu Park
Hyunsoo Chung
Si Hyung Lee
Jae Myung Park
Jung Ho Park
Gwang Ha Kim
Sung Kwan Shin
Su Jin Hong
Kwang Jae Lee
Moo In Park
Hye-Kyung Jung
Hyun-Soo Kim
Jae Kyu Sung
Seong Woo Jeon
Suck Chei Choi
Jeong Seop Moon
Nayoung Kim
Jong-Jae Park
Sung Hee Hong
Na Young Kim
Hwoon-Yong Jung
[J]. BMC Gastroenterology, 23
[30] Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis
Castell, DO
Kahrilas, PJ
Richter, JE
Vakil, NB
Johnson, DA
Zuckerman, S
Skammer, W
Levine, JG
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (03): : 575 - 583

← 1 2 3 4 5 →